SCM
HZNP

Suvretta Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Suvretta Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-786,313
Closed -$91M – 101
2023
Q3 		$91M Sell
786,313
-7,042
-0.9% -$757K 4.92% 4
2023
Q2 		$81.6M Sell
793,355
-180,400
-19% -$19M 4.36% 4
2023
Q1 		$106M Buy
973,755
+99,464
+11% +$11M 4.49% 4
2022
Q4 		$99.5M Buy
874,291
+161,730
+23% +$13.4M 4.18% 4
2022
Q3 		$44.1M Buy
712,561
+225,900
+46% +$15.8M 1.83% 25
2022
Q2 		$38.8M Buy
+486,661
New +$46.1M 1.48% 29

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.05B AUM 19.75% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Suvretta Capital Management's HZNP Position: Q4 2023 in Review

Suvretta Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 786,313 shares — an estimated $91M sold.

Suvretta Capital Management first reported a position in HZNP in Q2 2022 and held it in 6 quarters. The position peaked at $106M in Q1 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Suvretta Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Suvretta Capital Management sold 786,313 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $91M.
  • Suvretta Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2022 and held it in 6 quarters.
  • Suvretta Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $106M in Q1 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Suvretta Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.